新疆医科大学学报

参考文献

[1] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA CancerClin,2024,74(3):229-263.

[2] WALBOOMERS J M,JACOBS M V,MANOS M M,et al.Human papillomavirus is a necessary cause of invasive cervical cancer worldwide[J].Pathol,1999,189(1):12-19.

[3] ARBYN M,WEIDERPASS E,BRUNI L,et al.Estimates of incidence and mortality of cervical cancer in 2018:a worldwide analysis[J].Lancet Glob Health,2020,8(2):191-203.

[4] CANFELL K,KIM J J,BRISSON M,et al.Mortality impact of achieving WHO cervical cancer elimination targets:a comparative modelling analysis in 78 low-income and lower-middle-income countries[J].Lancet,2020,395(10224):591-603.

[5] COUVREUR K,NAERT E,DEJAEGHERE E,et al.Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates[J].BMC Cancer,2018,18(1):1101.

[6] WENTZENSEN N,CLARKE M A.Cervical cancer screening-past,present,and future[J].Cancer Epidemiol Biomarkers Prev,2021,30(3):432-434.

[7] WHO.WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention,second edition[M].Geneva:World Health Organization.2021,24-25.

[8] 任文辉，赵雪莲，赵方辉.全球宫颈癌筛查指南制定现状的系统综述[J].中华医学杂志，2021,101(24):1882-1889.

[9] ARBYN M,SMITH S B,TEMIN S,et al.Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples:updated meta-analyses[J].BMJ,2018,363:4823.

[10] COSTA S,VERBERCKMOES B,CASTLE P E,et al.Offering HPV self-sampling kits:an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening[J].Br J Cancer,2023,128(5):805-813.

[11] SHAH U J,NASIRUDDIN M,DAR S A,et al.Emerging biomarkers and clinical significance of HPV genotyping in prevention and management of cervical cancer[J].Microb Pathog,2020,143:104131.

[12] NELSON C W,MIRABELLO L.Human papillomavirus genomics:Understanding carcinogenicity[J].Tumour Virus Res,2023,15:200258.

[13] DE SANJOSE S,BROTONS M,PAVóN M A.The natural history of human papillomavirus infection[J].Best Pract Res Clin Obstet Gynaecol,2018,47:2-13.

[14] DOVNIK A,REPSE FA.The role of p16/Ki67 dual staining in cervical cancer screening[J].Curr Issues Mol Biol,2023,45(10):8476-8491.

[15] WENTZENSEN N,CLARKE M A,BREMER R,et al.Clinical evaluation of human papillomavirus screening with p16/Ki-67 dual stain triage in a large organized cervical cancer screening pogram[J].JAMA Intern Med,2019,179(7):881-888.

[16] CLARKE M A,CHEUNG L C,CASTLE P E,et al.Five-year risk of cervical precancer following p16/ki-67 dual-stain triage of hpv-positive women[J].JAMA Oncol,2019,5(2):181-186.

[17] HOPPE-SEYLER K,BOSSLER F,BRAUN J A,et al.The HPV E6/E7 oncogenes:key factors for viral carcinogenesis and therapeutic targets[J].Trends Microbiol,2018,26(2):158-168.

[18] WHITE C,REYNOLDS S,MURPHY K,et al.Performance of the HPV E6/E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening:Results from the CERVIVA HPV primary screening study in Ireland[J].Int J Cancer,2024,154(1):53-64.

[19] ARBYN M,SIMON M,DE SANJOSE S,et al.Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening:a systematic review and meta-analysis[J].Lancet Oncol,2022,23(7):950-960.

[20] KUMAR A,RATHI E,HARIHARAPURA R C,et al.Is viral E6 oncoprotein a viable target?A critical analysis in the context of cervical cancer[J].Med Res Rev,2020,40(5):2019-2048.

[21] RANASINGHE V,MCMILLAN N.Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer[J].Crit Rev Oncol Hematol,2025,211:104721.

[22] AGORASTOS T,CHATZISTAMATIOU K,MOYSIADIS T,et al.Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women,in comparison to genotyping and cytology.Final results of the PIPAVIR study[J].Int Cancer,2017,141(3):519-530.

[23] DOWNHAM L,JAAFAR I,ROL M L,et al.Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions:a systematic literature review and meta-analysis[J].Br Cancer,2024,130(4):517-525.

[24] MIRABELLO L,SUN C,GHOSH A,et al.Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population [J].Natl Cancer Inst,2012,104(7):556-565.

[25] WENTZENSEN N,SHERMAN M E,SCHIFFMAN M,et al.Utility of methylation markers in cervical cancer early detection:appraisal of the state-of-the-science[J].Gynecol Oncol,2009,112(2):293-299.

[26] COOK D A,KRAJDEN M,BRENTNALL A R,et al.Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial [J].Int J Cancer,2019,144(10):2587-2595.

[27] SZALMAS A,KONYA J.Epigenetic alterations in cervical carcinogenesis[J].Semin Cancer Biol,2009,19(3):144-152.

[28] SCHREIBERHUBER L,BARRETT J E,WANG J,et al.Cervical cancer screening using DNA methylation triage in a real-world population[J].Nat Med,2024,30(8):2251-2257.

[29] SALTA S,LOBO J,MAGALHAES B,et al.DNA methylation as a triage marker for colposcopy referral in HPV-based cervical cancer screening:a systematic review and meta-analysis[J].Clin Epigenetics,2023,15(1):125.

[30] CHEN M,WANG Y,WANG Q,et al.Impact of human and artificial intelligence collaboration on workload reduction in medical image interpretation[J].NPJ Digit Med,2024,7(1):349.

[31] WANG J,YU Y,TAN Y,et al.Artificial intelligence enables precision diagnosis of cervical cytology grades and cervical cancer[J].Nat Commun,2024,15(1):4369.

[32] WU A,XUE P,ABULIZI G,et al.Artificial intelligence in colposcopic examination:A promising tool to assist junior colposcopists[J].Front Med (Lausanne),2023,10:1060451.

[33] WU T,LUCAS E,ZHAO F,et al.Artificial intelligence strengthenes cervical cancer screeningpresent and future[J].Cancer Biol Med,2024,21(10):864-879.

[34] BRUNI L,SERRANO B,ROURA E,et al.Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide:a review and synthetic analysis[J].Lancet Glob Health,2022,10(8):1115-1127.

[35] ZHANG M,ZHONG Y,ZHAO Z,et al.Cervical cancer screening rates among Chinese women-China,2015 [J].China CDC Wkly,2020,2(26):481-486.

[36] ZHANG M,ZHONG Y,WANG L,et al.Cervical cancer screening coverage-China,2018-2019 [J].China CDC Wkly,2022,4(48):1077-1082.

[37] ASGARY R,BEIDECK E,NADERI R.Comparative assessment of test characteristics of cervical cancer screening methods for implementation in low-resource settings[J].Prev Med,2022,154:106883.

[38] CASTLE P E,EINSTEIN M H,SAHASRABUDDHE V V.Cervical cancer prevention and control in women living with human immunodeficiency virus[J].CA Cancer J Clin,2024,71(6):505-526.

[39] SHARMA K,MACHALEK D A,TOH Z Q,et al.No woman left behind:achieving cervical cancer elimination among women living with HIV[J].Lancet HIV,2023,10(6):412-420.

[40] KHARSANY A B,KARIM Q A.HIV infection and AIDS in sub-Saharan Africa:current status,challenges and opportunities[J].Open AIDS,2016;10:34-48.

[41] KOHLER R E,ELLIOTT T,MONARE B,et al.HPV self-sampling acceptability and preferences among women living with HIV in Botswana[J].Int Gynaecol Obstet.2019,147(3):332-338.

[42] GOLDSTEIN A,GERSH M,SKOVRONSKY G,et al.The future of cervical cancer screening[J].Int J Womens Health,2024,16:1715-1731.

[43] ARBYN M,SIMON M,PEETERS E,et al.2020 list of human papillomavirus assays suitable for primary cervical cancer screening[J].Clin Microbiol Infect,2021,27(8):1083-1095.

[44] POLJAK M,OSTRBENK V A,CUSCHIERI K,et al.2023 global inventory of commercial molecular tests for human papillomaviruses (HPV) [J].Clin Virol,2024,172:105671.

[45] 冯瑞梅，陈汶，乔友林.高危型人乳头瘤病毒核酸体外检测试剂盒临床功能验证的中美指导原则解读[J].中华肿瘤杂志，2017,39(7):553-557.

[46] CHADWICK V,BENNETT K F,MCCAFFERY K J,et al.Psychosocial impact of testing human papillomavirus positive in Australia's human papillomavirus-based cervical screening program:A cross-sectional survey[J].Psychooncology,2022,31(7):1110-1119.